PRW Wealth Management’s Invesco Biotechnology & Genome ETF PBE Stock Holding History

PRW Wealth Management’s Portfolio PBE Stock Details PBE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-3,300	Closed	-$208K	–	114
2023 Q2	$208K	Hold	3,300	–	–	0.07%	75
2023 Q1	$207K	Hold	3,300	–	–	0.08%	106
2022 Q4	$210K	Buy	+3,300	New	+$209K	0.09%	63

Other funds holding PBE

GKWIM

Gerber Kawasaki Wealth & Investment Management Santa Monica, California $3.14B AUM 22.62% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

CreativeOne Wealth Overland Park, Kansas $4.31B AUM 19.42% 1-Year Est. Return

YIA

YHB Investment Advisors West Hartford, Connecticut $1.56B AUM 27.39% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

PRW Wealth Management's PBE Position: Q3 2023 in Review

PRW Wealth Management sold out of Invesco Biotechnology & Genome ETF (PBE) in Q3 2023, closing a stake of 3,300 shares — an estimated $208K sold.

PRW Wealth Management first reported a position in PBE in Q4 2022 and held it in 3 quarters. The position peaked at $210K in Q4 2022. 97 funds tracked by Wall St. Rank hold PBE as of Q3 2023.

PRW Wealth Management reported no remaining Invesco Biotechnology & Genome ETF position as of Q3 2023 after selling out during the quarter.
PRW Wealth Management sold 3,300 Invesco Biotechnology & Genome ETF shares in Q3 2023, an estimated $208K.
PRW Wealth Management first reported a position in Invesco Biotechnology & Genome ETF in Q4 2022 and held it in 3 quarters.
PRW Wealth Management's Invesco Biotechnology & Genome ETF position peaked at $210K in Q4 2022.
97 funds tracked by Wall St. Rank held Invesco Biotechnology & Genome ETF as of Q3 2023.

Based on PRW Wealth Management's 13F filing for Q3 2023, filed 1 Nov 2023.